Literature DB >> 15877721

Subjective experiences on antipsychotic medications: synthesis and conclusions.

S R Marder1.   

Abstract

OBJECTIVE: This report synthesizes the literature describing the phenomenology, clinical importance and biology of subjective responses to antipsychotic medications in schizophrenia. A patient's experience of an antipsychotic is important because unpleasant or dysphoric responses can impair therapeutic relationships, lead to medication non-adherence, and have direct negative effects on a patient's quality of life.
METHOD: The author selectively reviewed early studies of subjective responses to antipsychotics and integrated this literature with the work of the other investigators in this special section.
RESULTS: There is substantial evidence that second-generation antipsychotics have advantages in causing fewer dysphoric responses when compared with first-generation agents. Clinical and neuroimaging studies suggest that dopamine blockade is an important determinant of many of these dysphorias. At this point in time it is unclear whether dysphoria results from extrapyramidal symptoms--particularly akathisia and akinesia--or whether they are a direct result of decreased dopamine activity.
CONCLUSION: Clinicians and researchers should continue to monitor dysphorias in schizophrenia. Contributions by the authors in this supplement provide new and more refined methods for measuring subjective responses in future studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15877721     DOI: 10.1111/j.1600-0447.2005.00544.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  6 in total

1.  Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.

Authors:  Christian G Widschwendter; Georg Kemmler; Maria A Rettenbacher; Nursen Yalcin-Siedentopf; Alex Hofer
Journal:  BMC Psychiatry       Date:  2018-06-28       Impact factor: 3.630

2.  Effect of risperidone versus haloperidol on emotional responding in schizophrenic patients.

Authors:  E Fakra; S Khalfa; D Da Fonseca; N Besnier; P Delaveau; J M Azorin; O Blin
Journal:  Psychopharmacology (Berl)       Date:  2008-06-25       Impact factor: 4.530

3.  Subjectivity in the perception and measurement of quality of life: conceptualization and development of the Seville questionnaire.

Authors:  Jose Giner; Elena Ibáñez; Dolores Franco; Renato D Alarcón
Journal:  Psychiatr Q       Date:  2008-10-07

4.  Impact of depressive symptoms on subjective well-being: the importance of patient-reported outcomes in schizophrenia.

Authors:  Jorge Mauriño; Julio Sanjúan; Josep Maria Haro; Teresa Díez; Javier Ballesteros
Journal:  Patient Prefer Adherence       Date:  2011-09-27       Impact factor: 2.711

5.  Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics.

Authors:  Nursen Yalcin-Siedentopf; Fabienne Wartelsteiner; Alexandra Kaufmann; Falko Biedermann; Monika Edlinger; Georg Kemmler; Maria A Rettenbacher; Christian G Widschwendter; Gerald Zernig; W Wolfgang Fleischhacker; Alex Hofer
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-07       Impact factor: 5.176

6.  Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.

Authors:  Sanne Wulff; Lars Hageman Pinborg; Claus Svarer; Lars Thorbjørn Jensen; Mette Ødegaard Nielsen; Peter Allerup; Nikolaj Bak; Hans Rasmussen; Erik Frandsen; Egill Rostrup; Birte Yding Glenthøj
Journal:  Schizophr Bull       Date:  2015-02-18       Impact factor: 9.306

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.